Zoetis Inc. (NYSE: ZTS) announced that its top executives will address investors at an upcoming industry event. The company confirmed participation in the Morgan Stanley 24th Annual Global Healthcare Conference.

Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, are scheduled for a fireside chat. The session is set for Monday, September 14, 2026, at 1:50 pm ET.

Event Access Details

Interested parties can access the live audio webcast of the presentation. The stream will be available on the Zoetis investor relations website. A replay of the session will also be hosted on the company’s website following the conclusion of the event.

About Zoetis

Zoetis operates as the world’s leading animal health company. The firm focuses on predicting, preventing, detecting, and treating animal illness. It supports veterinarians, livestock producers, and pet owners in over 100 countries. The company integrates scientific expertise with data-driven R&D to deliver innovations in medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions.

Zoetis Inc. announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Simparica Trio to treat infestations caused by New World screwworm (Cochliomyia hominivorax) larvae in dogs and puppies. This regulatory milestone provides veterinarians with a critical tool to address a parasite that feeds on living tissues and can cause severe damage or death if untreated.

The authorization comes as New World screwworm continues to threaten animal health in the US, prompting several states to issue formal orders requiring treatment of domestic animals moving from infested areas. Under the EUA framework, the FDA permits the use of medications in emergencies to treat life-threatening conditions when specific criteria are met.

Multi-Species Response Strategy

Zoetis is deploying a coordinated response across both companion animals and livestock sectors. While Simparica Trio targets dogs, the company also offers Dectomax-CA1 Injectable (doramectin injection) for cattle. This product holds conditional approval for preventing and treating NWS larvae infestations in beef cattle, female dairy cattle under 20 months of age, pregnant beef cows, newborn calves, and bulls.

Additionally, the FDA issued separate EUAs for Dectomax/Dectomax-CA1 for use in other species:

• Dairy cattle (lactating cows, dry cows, and heifers 20 months or older)
• Swine, sheep (excluding lactating sheep), and deer for prevention
• Horses aged 1 year or older for prevention

Simparica Trio remains FDA-approved for its standard indications, including prevention of heartworm disease and control of ticks, fleas, roundworms, and hookworms. It is indicated for dogs and puppies 8 weeks of age and older weighing 2.8 pounds or greater.

Regulatory and Safety Considerations

The EUA for Simparica Trio is valid only for the duration of the emergency declaration under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act. The product is not fully approved for this specific use.

Safety data indicates that Simparica Trio contains sarolaner, an isoxazoline associated with neurologic adverse reactions such as tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. Use requires caution in dogs with a seizure history. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. Safe use has not been evaluated in breeding, pregnant, or lactating dogs.

For livestock treatments, withdrawal periods apply. Dectomax-CA1 requires a 35-day pre-slaughter withdrawal period for cattle, sheep, and deer, and a 24-day period for swine. Milk from dairy cattle must be withheld for 468 hours (19.5 days) after treatment ends.